Archive · 6 Jan 2026
FDA Introduces 'Chain of Risk' Framework for Tobacco Regulation
The FDA has introduced a new way to regulate tobacco products called the 'chain of risk.'
This system ranks tobacco products from high to low risk based on things like how much nicotine they have, how they are used, and how addictive they are.
The goal is to protect young people and help smokers who can't quit by focusing on the most harmful products.
The FDA wants a clear market where safer products are properly regulated.
This approach is different from the World Health Organization's, which is more restrictive.
In India, this new strategy could offer safer options for smokers and support existing tobacco control efforts.
Some countries, including India, are discussing whether harm reduction should be part of global tobacco control policies.
The FDA introduced a 'chain of risk' framework to classify tobacco products based on their relative harm to public health.
The framework evaluates factors such as nicotine content, toxic substance content, mode of use, and potential for addiction.
The goal is to protect youth and support smokers who cannot quit by focusing on the most harmful products.
The FDA advocates for a transparent, regulated market where risk-reducing products are properly licensed.
The WHO's restrictive stance differs from the FDA's approach, with some countries advocating for harm reduction strategies.
- Who
- U.S. Food and Drug Administration (FDA)
- What
- Introduction of a 'chain of risk' framework to classify and regulate tobacco products based on their relative harm to public health
- When
- Not specified
- Where
- United States, with implications for global tobacco control strategies, including India
- Why
- To identify the most harmful products, allocate control resources effectively, and reduce risks from unregulated products
- Organization
- U.S. Food and Drug Administration (FDA)
- Framework
- Chain of Risk
- Purpose
- Classify and regulate tobacco products based on relative harm
- Factors Considered
- Nicotine content, toxic substance content, mode of use, addiction potential, long-term effects
- Key Focus
- Protecting youth and supporting smokers who cannot quit
- Global Context
- WHO's restrictive stance vs. FDA's regulated market approach
- Indian Perspective
- Potential for regulated alternatives to complement tobacco control efforts